Clinical Trial

Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome

Study acronym: GRAAL
Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 29, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the drug absorption of oral antibiotics in patients with short bowel syndrome.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-03-21; most recent amendment 2024-08-28.
Status change: Not Yet Recruiting → Recruiting 2023-02-10
Trial Details
NCT Number NCT05302531
Lead Sponsor Central Hospital, Nancy, France
Collaborators: Société Francophone Nutrition Clinique et Métabolisme, FIlière des Maladies rares Abdomino-THOraciques, Fresenius Kabi
Conditions Short Bowel Syndrome, Infection, Bacterial
Enrollment 10 participants
Start Date 2022-12-09
Primary Completion 2024-12 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2024-08-29